SCHEMBL15869784

SCHEMBL15869784

Cc1ccc2c(c1)Cc1cc(O)ccc1-2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 1/20 0.58
ESR2 Q92731 5/20 0.56
ESR1 P03372 4/20 0.56
MAOA P21397 3/20 0.51
MAOB P27338 3/20 0.51
DRD2 P14416 4/20 0.48
DRD1 P21728 4/20 0.48
DRD5 P21918 4/20 0.48
DRD3 P35462 4/20 0.48
CYP17A1 P05093 1/20 0.48
METAP1 P53582 1/20 0.47
DRD4 P21917 2/20 0.43
MIF P14174 1/20 0.43
MAPT P10636 2/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
ACHE P22303 2/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8771857 0.92 HSD17B1 (0.54) HSD17B1ESR2ESR1MAOAMAOB
SCHEMBL803069 0.88 MIF (0.54) HSD17B1ESR2ESR1MAOAMAOB
SCHEMBL29633547 0.87 METAP1 (0.57) HSD17B1ESR2ESR1MAOAMAOB
SCHEMBL4897556 0.87 METAP1 (0.57) HSD17B1ESR2ESR1MAOAMAOB
SCHEMBL29439100 0.87 HSD17B1 (0.64) HSD17B1ESR2ESR1MAOAMAOB
SCHEMBL788852 0.87 HSD17B1 (0.64) HSD17B1ESR2ESR1MAOAMAOB
SCHEMBL12704854 0.83 ESR1 (0.47) HSD17B1ESR2ESR1MAOAMAOB
SCHEMBL26767709 0.82 ESR2 (0.44) HSD17B1ESR2ESR1MAOAMAOB
SCHEMBL26767879 0.82 ESR1 (0.44) HSD17B1ESR2ESR1MAOAMAOB
SCHEMBL29332473 0.82 METAP1 (0.53) HSD17B1ESR2ESR1MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9366906-B2 Photoreactive compounds ROLIC AG (CH) 2016-06-14 US disclosed
US-20150030540-A1 Imaging agents for detecting neurological dysfunction LILLY CO ELI (US) 2015-01-29 US disclosed
US-8932557-B2 Imaging agents for detecting neurological dysfunction ELI LILLY AND COMPANY (US) 2015-01-13 US disclosed
US-20140192305-A1 PHOTOREACTIVE COMPOUNDS ROLIC AG (CH) 2014-07-10 US disclosed
US-20120302755-A1 Imaging Agents for Detecting Neurological Dysfunction SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2012-11-29 US disclosed
US-8318132-B2 Imaging agents for detecting neurological dysfunction SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2012-11-27 US disclosed
US-20110091382-A1 NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION SIEMENS MEDICAL SOLUTION USA, INC. 2011-04-21 US disclosed
US-20110046378-A1 Novel Imaging Agents for Detecting Neurological Dysfunction SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110091382-A1 NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION FABP7, TSPO, SLC18A3 HSD17B1 767/4885ESR2 2832/4885ESR1 2665/4885
US-20110046378-A1 Novel Imaging Agents for Detecting Neurological Dysfunction FABP7, SLC18A3, TSPO HSD17B1 817/4885ESR2 2656/4885ESR1 2563/4885
US-20140192305-A1 PHOTOREACTIVE COMPOUNDS PCNA, CRY1, CRY2 HSD17B1 4647/4885ESR2 2974/4885ESR1 1440/4885
US-20150030540-A1 Imaging agents for detecting neurological dysfunction SLC18A3, TSPO, CHAT HSD17B1 1603/4885ESR2 3360/4885ESR1 4226/4885
US-20120302755-A1 Imaging Agents for Detecting Neurological Dysfunction SLC18A3, TSPO, CHAT HSD17B1 1603/4885ESR2 3360/4885ESR1 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.